Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors (Q22305941)

Expert Review of Anti-infective Therapy

Europe PubMed Central

title

Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors (English)

0 references

Aeron C Hurt

1

Aeron C

Hurt

1 reference

7 February 2023

Ian Barr

3

Ian

Barr

1 reference

7 February 2023

Hui-Ting Ho

2

Hui-Ting

Ho

1 reference

7 February 2023

language of work or name

English

0 references

publication date

October 2006

0 references

published in

0 references

volume

4

0 references

issue

5

0 references

page(s)

795-805

0 references

cites work

Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Potential impact of antiviral drug use during influenza pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

The impact of influenza epidemics on mortality: introducing a severity index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Influenza: diagnosis, management, and prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Developing vaccines against pandemic influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

The M2 proton channels of influenza A and B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Antiviral resistance in influenza viruses--implications for management and pandemic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Rational design of potent sialidase-based inhibitors of influenza virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Neuraminidase inhibitors for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Frequency of Amantadine-Resistant Influenza A Viruses during Two Seasons Featuring Cocirculation of H1N1 and H3N2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Low incidence of rimantadine resistance in field isolates of influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Emergence and transmission of amantadine-resistant influenza A in a nursing home.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Resistance of influenza viruses to neuraminidase inhibitors--a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Recovery of drug-resistant influenza virus from immunocompromised patients: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Position statement: global neuraminidase inhibitor susceptibility network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Anti-virals for influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

A single sequence change destabilizes the influenza virus neuraminidase tetramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Re-emergence of fatal human influenza A subtype H5N1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Avian flu: isolation of drug-resistant H5N1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Oseltamivir resistance during treatment of influenza A (H5N1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Inhibition of influenza virus production in virus-infected mice by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Mechanism of action of T-705 against influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

The molecular basis of the specific anti-influenza action of amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021

High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021

Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021

Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021

Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021

Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021

Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021

Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021

Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021

Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021

Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.795

7 January 2021